Published in Am J Physiol Gastrointest Liver Physiol on July 21, 2005
Inflammatory mediators in gastroesophageal reflux disease: impact on esophageal motility, fibrosis, and carcinogenesis. Am J Physiol Gastrointest Liver Physiol (2010) 1.20
Inflammation and oxidative stress in gastroesophageal reflux disease. J Clin Biochem Nutr (2007) 1.03
Long-term maintenance effect of radiofrequency energy delivery for refractory GERD: a decade later. Surg Endosc (2014) 0.95
HCl-induced and ATP-dependent upregulation of TRPV1 receptor expression and cytokine production by human esophageal epithelial cells. Am J Physiol Gastrointest Liver Physiol (2012) 0.92
Gastroesophageal reflux disease--from reflux episodes to mucosal inflammation. Nat Rev Gastroenterol Hepatol (2011) 0.91
HCl-activated neural and epithelial vanilloid receptors (TRPV1) in cat esophageal mucosa. Am J Physiol Gastrointest Liver Physiol (2009) 0.90
Viewpoints on Acid-induced inflammatory mediators in esophageal mucosa. J Neurogastroenterol Motil (2010) 0.89
HCl-induced inflammatory mediators in esophageal mucosa increase migration and production of H2O2 by peripheral blood leukocytes. Am J Physiol Gastrointest Liver Physiol (2010) 0.88
ATP: a mediator for HCl-induced TRPV1 activation in esophageal mucosa. Am J Physiol Gastrointest Liver Physiol (2011) 0.85
Barrier effect of Esoxx(®) on esophageal mucosal damage: experimental study on ex-vivo swine model. Clin Exp Gastroenterol (2012) 0.83
Ulcerative colitis. N Engl J Med (2011) 6.14
VEGF-A links angiogenesis and inflammation in inflammatory bowel disease pathogenesis. Gastroenterology (2008) 2.53
A murine model of chronic inflammation-induced intestinal fibrosis down-regulated by antisense NF-kappa B. Gastroenterology (2003) 2.53
Angiogenesis as a novel component of inflammatory bowel disease pathogenesis. Gastroenterology (2006) 2.35
Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis. Proc Natl Acad Sci U S A (2010) 2.22
Etiopathogenesis of inflammatory bowel diseases. World J Gastroenterol (2006) 1.79
Immune regulation by microvascular endothelial cells: directing innate and adaptive immunity, coagulation, and inflammation. J Immunol (2007) 1.64
Inflammatory bowel disease: the role of environmental factors. Autoimmun Rev (2004) 1.61
The emergence of inflammatory bowel disease in the Asian Pacific region. Curr Opin Gastroenterol (2005) 1.55
Intestinal fibrosis in IBD--a dynamic, multifactorial process. Nat Rev Gastroenterol Hepatol (2009) 1.51
Platelets in inflammatory bowel disease: clinical, pathogenic, and therapeutic implications. Am J Gastroenterol (2004) 1.51
Challenges in pediatric inflammatory bowel disease. Inflamm Bowel Dis (2006) 1.49
Inflammation-induced endothelial-to-mesenchymal transition: a novel mechanism of intestinal fibrosis. Am J Pathol (2011) 1.45
Reactive oxygen species are messengers in maintenance of human and guinea pig gallbladder tonic contraction. Am J Physiol Gastrointest Liver Physiol (2007) 1.44
cAMP-response element-binding protein mediates acid-induced NADPH oxidase NOX5-S expression in Barrett esophageal adenocarcinoma cells. J Biol Chem (2006) 1.42
Platelets trigger a CD40-dependent inflammatory response in the microvasculature of inflammatory bowel disease patients. Gastroenterology (2003) 1.42
Gastroesophageal reflux disease-associated esophagitis induces endogenous cytokine production leading to motor abnormalities. Gastroenterology (2006) 1.41
Inflammatory bowel disease: progress and current concepts of etiopathogenesis. J Dig Dis (2007) 1.30
Platelet-derived hyaluronidase 2 cleaves hyaluronan into fragments that trigger monocyte-mediated production of proinflammatory cytokines. Am J Pathol (2009) 1.27
Interleukin 1beta-induced production of H2O2 contributes to reduced sigmoid colonic circular smooth muscle contractility in ulcerative colitis. J Pharmacol Exp Ther (2004) 1.27
Angiogenesis blockade as a new therapeutic approach to experimental colitis. Gut (2006) 1.26
Management consensus of inflammatory bowel disease for the Asia-Pacific region. J Gastroenterol Hepatol (2006) 1.23
Role of a novel bile acid receptor TGR5 in the development of oesophageal adenocarcinoma. Gut (2009) 1.20
Inflammatory mediators in gastroesophageal reflux disease: impact on esophageal motility, fibrosis, and carcinogenesis. Am J Physiol Gastrointest Liver Physiol (2010) 1.20
VEGF-C-dependent stimulation of lymphatic function ameliorates experimental inflammatory bowel disease. J Clin Invest (2014) 1.20
MAPK mediates PKC-dependent contraction of cat esophageal and lower esophageal sphincter circular smooth muscle. Am J Physiol Gastrointest Liver Physiol (2003) 1.18
CD40-mediated immune-nonimmune cell interactions induce mucosal fibroblast chemokines leading to T-cell transmigration. Gastroenterology (2004) 1.18
TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn's disease. J Immunol (2006) 1.17
Cutting edge: T cells trigger CD40-dependent platelet activation and granular RANTES release: a novel pathway for immune response amplification. J Immunol (2004) 1.17
Proinflammatory cytokines alter/reduce esophageal circular muscle contraction in experimental cat esophagitis. Am J Physiol Gastrointest Liver Physiol (2004) 1.17
Inflammatory bowel disease: Established and evolving considerations on its etiopathogenesis and therapy. J Dig Dis (2010) 1.12
Signal transducers and activators of transcription 3 signaling pathway: an essential mediator of inflammatory bowel disease and other forms of intestinal inflammation. Inflamm Bowel Dis (2005) 1.10
Signal-transduction pathways that regulate smooth muscle function I. Signal transduction in phasic (esophageal) and tonic (gastroesophageal sphincter) smooth muscles. Am J Physiol Gastrointest Liver Physiol (2005) 1.09
NADPH oxidase NOX5-S mediates acid-induced cyclooxygenase-2 expression via activation of NF-kappaB in Barrett's esophageal adenocarcinoma cells. J Biol Chem (2007) 1.06
Platelet activation and the CD40/CD40 ligand pathway: mechanisms and implications for human disease. Crit Rev Immunol (2005) 1.04
Inflammatory bowel disease: autoimmune or immune-mediated pathogenesis? Clin Dev Immunol (2004) 1.04
Themes in fibrosis and gastrointestinal inflammation. Am J Physiol Gastrointest Liver Physiol (2011) 1.03
An oral supplement enriched with fish oil, soluble fiber, and antioxidants for corticosteroid sparing in ulcerative colitis: a randomized, controlled trial. Clin Gastroenterol Hepatol (2005) 1.03
Hyaluronan (HA) deposition precedes and promotes leukocyte recruitment in intestinal inflammation. Clin Transl Sci (2008) 1.02
Closing fistulas in Crohn's disease--should the accent be on maintenance or safety? N Engl J Med (2004) 1.02
Abnormal motility in patients with ulcerative colitis: the role of inflammatory cytokines. Arch Surg (2002) 1.02
Acid-induced p16 hypermethylation contributes to development of esophageal adenocarcinoma via activation of NADPH oxidase NOX5-S. Am J Physiol Gastrointest Liver Physiol (2010) 0.98
Corticotropin-releasing hormone family of peptides regulates intestinal angiogenesis. Gastroenterology (2010) 0.97
Etiopathogenesis of inflammatory bowel disease: the importance of the pediatric perspective. Inflamm Bowel Dis (2002) 0.97
Intestinal fibrosis in inflammatory bowel disease - Current knowledge and future perspectives. J Crohns Colitis (2008) 0.96
Redox equilibrium in mucosal T cells tunes the intestinal TCR signaling threshold. J Immunol (2005) 0.95
Advances in therapeutic interventions targeting the vascular and lymphatic endothelium in inflammatory bowel disease. Curr Opin Gastroenterol (2013) 0.95
Animal models of intestinal fibrosis: new tools for the understanding of pathogenesis and therapy of human disease. Am J Physiol Gastrointest Liver Physiol (2012) 0.93
Role of progesterone signaling in the regulation of G-protein levels in female chronic constipation. Gastroenterology (2005) 0.93
p53 negatively regulates intestinal immunity by delaying mucosal T cell cycling. J Clin Invest (2002) 0.93
Abnormalities of prostaglandins and cyclooxygenase enzymes in female patients with slow-transit constipation. Gastroenterology (2007) 0.93
Acid-induced release of platelet-activating factor by human esophageal mucosa induces inflammatory mediators in circular smooth muscle. J Pharmacol Exp Ther (2006) 0.93
HCl-induced inflammatory mediators in cat esophageal mucosa and inflammatory mediators in esophageal circular muscle in an in vitro model of esophagitis. Am J Physiol Gastrointest Liver Physiol (2006) 0.92
Platelet-activating factor and prostaglandin E2 impair esophageal ACh release in experimental esophagitis. Am J Physiol Gastrointest Liver Physiol (2005) 0.92
HCl-induced and ATP-dependent upregulation of TRPV1 receptor expression and cytokine production by human esophageal epithelial cells. Am J Physiol Gastrointest Liver Physiol (2012) 0.92
Critical role of caspases in the regulation of apoptosis and proliferation of mucosal T cells. Gastroenterology (2002) 0.92
Intestinal fibrosis in inflammatory bowel disease: progress in basic and clinical science. Curr Opin Gastroenterol (2008) 0.91
Fibrosis in ulcerative colitis: mechanisms, features, and consequences of a neglected problem. Inflamm Bowel Dis (2014) 0.91
Hydrogen peroxide reduces lower esophageal sphincter tone in human esophagitis. Gastroenterology (2005) 0.90
Retracted Role of STAT3 and vitamin D receptor in EZH2-mediated invasion of human colorectal cancer. J Pathol (2013) 0.90
HCl-activated neural and epithelial vanilloid receptors (TRPV1) in cat esophageal mucosa. Am J Physiol Gastrointest Liver Physiol (2009) 0.90